Spyre deprioritizes anti-TL1A drug SPY072 in RA after Phase 2 misses its bar; shares dip 12% as SKYLINE UC data nears in September.
August 26, 2026 07:00 AM EDT
Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data
Ayisha Sharma
News Reporter
Spyre Therapeutics said Tuesday it is deprioritizing its antibody candidate for rheumatoid arthritis (RA) after the drug missed the biotech’s bar for success in a …
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A…
Spyre Therapeutics shared Phase 2 SKYWAY trial data for SPY072 in rheumatoid arthritis. The therapy missed internal priority…
Spyre Therapeutics took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage…
Incyte drops JAK2 drug INCB160058 after data review; Oak Hill Bio merges with RA Capital SPAC for $175M; Innocare's…
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock…
The process of negotiating drug reimbursements is opaque and drawn-out
